The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

NCT04312997 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: PUL-042 Inhalation Solution
DRUG: Placebo

Sponsor

Pulmotect, Inc.

Collaborators

[object Object]